01
May
2025
01
May
2025
Dry eye disease (DED), particularly evaporative types linked to Meibomian Gland Dysfunction (MGD), can significantly affect daily comfort and vision quality. A recent observational study evaluated the durability of Tixel® thermomechanical therapy, revealing sustained improvements in tear stability, gland function, and symptom relief six months after treatment. In this article, we explore these findings and what they mean for those seeking lasting solutions for dry eye symptoms.
2025 Sadri-et-al-durability-of-treatment-with-a-thermomechanical-device-in-meibomian-gland-dysfunction-an-observational.pdf
To view the full study please click here.
MGD is a major contributor to evaporative DED, affecting over 75% of dry eye patients aged over 40.
Traditional treatments like warm compresses often fall short due to inconsistent temperatures and low compliance.
Tixel® offers a modern, in-office thermomechanical solution, delivering precise heat pulses to enhance meibomian gland function without contacting the eye’s surface.
Key Points:
This extension study followed subjects from a prior pivotal trial who had shown early improvements in tear break-up time (TBUT).
Participants underwent three sessions of Tixel® treatment and were evaluated six months post-treatment.
21 subjects (42 eyes), mostly aged 39–81 years, were observed without any additional interventions during this time.
Effectiveness Outcomes:
Tear Stability (TBUT): Improved significantly from 4.0 to 9.2 seconds.
Meibomian Gland Score (MGS): Jumped from 6.6 to 24.8, indicating healthier gland secretions.
Ocular Surface Disease Index (OSDI): Symptom scores decreased by an average of 24.3 points, suggesting substantial relief.
Safety Outcomes:
No adverse ocular events reported.
Corneal health showed significant improvement, with reduced staining.
Best Corrected Visual Acuity (BCVA) remained stable throughout.
Key Points:
Unlike other thermal therapies like LipiFlow® and TearCare®, Tixel® demonstrated durable results without regression at the six-month mark.
Treatment is quick (only two minutes per session), non-invasive, and does not require direct eye contact.
Ideal for busy individuals seeking efficient, lasting dry eye relief.
The Tixel® device has proven itself as a safe and highly effective solution for patients suffering from evaporative dry eye due to MGD, offering clinically significant improvements that are maintained over six months. For anyone struggling with persistent dry eye symptoms, Tixel® presents a promising, durable treatment option.
Discover Why Top Clinics Are Choosing Tixel – Book Your In-clinic Consultation
What if you could offer your clients results comparable to fractional CO2 lasers – with minimal downtime, no light-based risks, and total comfort? With Tixel, now you can.
Already trusted by experts like Dr Sabrina and Dr Tapan across 7 Harley Street clinics, Tixel is quickly becoming the go-to choice for non-invasive skin rejuvenation.
Incomparable Technology, Uncompromised Results Tixel® is powered by Novoxel's proprietary TMA® technology – the only fractional skin resurfacing system to transfer thermal energy directly to the skin by conduction, the most effective form of heat transfer. A self-sterilising medical-grade titanium tip delivers precision heat to trigger natural collagen production and skin renewal.
Clinically proven with over 60 clinical studies and 30 published peer-reviewed papers
Arrange an in-clinic demonstration to explore how Tixel® can support your clinical outcomes
Read it? Loved it? Want to share it?
